JP2016533507A - 抗原受容体スクリーニングアッセイ - Google Patents

抗原受容体スクリーニングアッセイ Download PDF

Info

Publication number
JP2016533507A
JP2016533507A JP2016545238A JP2016545238A JP2016533507A JP 2016533507 A JP2016533507 A JP 2016533507A JP 2016545238 A JP2016545238 A JP 2016545238A JP 2016545238 A JP2016545238 A JP 2016545238A JP 2016533507 A JP2016533507 A JP 2016533507A
Authority
JP
Japan
Prior art keywords
antigen
cell
antigen receptor
receptor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016545238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533507A5 (OSRAM
Inventor
ワグナー，リチャード・ダブリュ
Original Assignee
エックス−ボディ インコーポレイテッド
エックス−ボディ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス−ボディ インコーポレイテッド, エックス−ボディ インコーポレイテッド filed Critical エックス−ボディ インコーポレイテッド
Publication of JP2016533507A publication Critical patent/JP2016533507A/ja
Publication of JP2016533507A5 publication Critical patent/JP2016533507A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N2021/7769—Measurement method of reaction-produced change in sensor
    • G01N2021/7773—Reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016545238A 2013-09-30 2014-09-26 抗原受容体スクリーニングアッセイ Pending JP2016533507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884348P 2013-09-30 2013-09-30
US61/884,348 2013-09-30
PCT/US2014/057672 WO2015048413A1 (en) 2013-09-30 2014-09-26 Antigen receptor screening assay

Publications (2)

Publication Number Publication Date
JP2016533507A true JP2016533507A (ja) 2016-10-27
JP2016533507A5 JP2016533507A5 (OSRAM) 2017-11-02

Family

ID=52744492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545238A Pending JP2016533507A (ja) 2013-09-30 2014-09-26 抗原受容体スクリーニングアッセイ

Country Status (6)

Country Link
US (2) US20160238613A1 (OSRAM)
EP (1) EP3052935A4 (OSRAM)
JP (1) JP2016533507A (OSRAM)
CN (1) CN105793705A (OSRAM)
CA (1) CA2924603A1 (OSRAM)
WO (1) WO2015048413A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162452A1 (ja) * 2019-02-04 2020-08-13 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122852A1 (en) * 2002-11-13 2007-05-31 Micromet Ag Method for identifying antigen specific b cells
WO2009139378A1 (ja) * 2008-05-12 2009-11-19 独立行政法人理化学研究所 イヌ又はヒトの抗原特異的IgEを定量する方法
WO2012014997A1 (ja) * 2010-07-30 2012-02-02 シスメックス株式会社 抗ｆｄｐモノクローナル抗体、それを用いたｆｄｐ測定用試薬及び試薬キット、並びにｆｄｐ測定方法
US20120107840A1 (en) * 2008-04-09 2012-05-03 Sru Biosystems, Inc Methods for Label Free Testing of Cells
JP2012518390A (ja) * 2009-02-24 2012-08-16 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
JP2012526998A (ja) * 2009-05-15 2012-11-01 エス アール ユー バイオシステムズ，インコーポレイテッド 細胞集団および混合細胞集団における変化の検出

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US20050208627A1 (en) * 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
US8298780B2 (en) * 2003-09-22 2012-10-30 X-Body, Inc. Methods of detection of changes in cells
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
FR2894983B1 (fr) * 2005-12-16 2012-08-17 Lab Francais Du Fractionnement Test de caracterisation des anticorps.
JP2009544332A (ja) * 2006-07-27 2009-12-17 ザ・コカ−コーラ・カンパニー 味覚調節物質を同定するためのモデル味覚細胞および使用方法
US8008031B2 (en) * 2007-12-19 2011-08-30 National Pingtung University Of Science And Technology Competitive receptor binding assay for detecting beta-glucans
US9880160B2 (en) * 2011-03-15 2018-01-30 X-Body, Inc. Antibody screening methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122852A1 (en) * 2002-11-13 2007-05-31 Micromet Ag Method for identifying antigen specific b cells
US20120107840A1 (en) * 2008-04-09 2012-05-03 Sru Biosystems, Inc Methods for Label Free Testing of Cells
WO2009139378A1 (ja) * 2008-05-12 2009-11-19 独立行政法人理化学研究所 イヌ又はヒトの抗原特異的IgEを定量する方法
JP2012518390A (ja) * 2009-02-24 2012-08-16 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
JP2012526998A (ja) * 2009-05-15 2012-11-01 エス アール ユー バイオシステムズ，インコーポレイテッド 細胞集団および混合細胞集団における変化の検出
WO2012014997A1 (ja) * 2010-07-30 2012-02-02 シスメックス株式会社 抗ｆｄｐモノクローナル抗体、それを用いたｆｄｐ測定用試薬及び試薬キット、並びにｆｄｐ測定方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162452A1 (ja) * 2019-02-04 2020-08-13 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
JPWO2020162452A1 (ja) * 2019-02-04 2021-02-18 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
US12241061B2 (en) 2019-02-04 2025-03-04 National University Corporation Ehime University CAR library and scFv manufacturing method

Also Published As

Publication number Publication date
CN105793705A (zh) 2016-07-20
EP3052935A1 (en) 2016-08-10
CA2924603A1 (en) 2015-04-02
EP3052935A4 (en) 2017-03-08
US20200174011A1 (en) 2020-06-04
WO2015048413A1 (en) 2015-04-02
US20160238613A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
US7094555B2 (en) Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
Kläsener et al. B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk
Xiao et al. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation
AU2009220203B2 (en) Gel microdrop composition and method of using the same
Bradshaw et al. Concurrent detection of secreted products from human lymphocytes by microengraving: cytokines and antigen-reactive antibodies
JP6891112B2 (ja) 免疫チェックポイントの調節因子を評価するためのシステム及び方法
Henry-Bonami et al. B lymphocyte “original sin” in the bone marrow enhances islet autoreactivity in type 1 diabetes–prone nonobese diabetic mice
US11440946B2 (en) Universal antibody-mediated biosensor
JP2007536522A (ja) Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
CN119661713A (zh) 一种能够激活t细胞活性的抗cd3纳米抗体及其制备方法与应用
US20200174011A1 (en) Antigen receptor screening assay
Funk et al. Interrogating ligand-receptor interactions using highly sensitive cellular biosensors
Patel et al. Evaluation of a fit-for-purpose assay to monitor antigen-specific functional CD4+ T-cell subpopulations in rheumatoid arthritis using flow cytometry–based peptide-MHC class-II tetramer staining
US20050048545A1 (en) Universal detection of binding
KR20210137128A (ko) 항체의 선택 방법
US20250306005A1 (en) Means and methods for determining cellular avidity
AU2014324783A1 (en) Antigen receptor screening assay
JP2005520156A (ja) β２ミクログロブリンのイムノアッセイ法
Yue et al. Novel cellular microarray assay for profiling T-cell peptide antigen specificities
Rokkam et al. Discovery and characterization of llama VHH targeting the RO form of human CD45
RU2845938C1 (ru) Клеточный анализ для определения активности киллинга опухолевых клеток, экспрессирующих химерные антигены иммунных клеток in vitro
JPH09501767A (ja) レセプター機能検定
US20250003973A1 (en) Synthetic constructs and methods for processing antigen-specific cells
JP2016533507A5 (OSRAM)
Priddey Characterisation of alloantibody-human leukocyte antigen interactions to improve immunological risk assessment in solid organ transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811